Incepta Pharmaceuticals – Quality Generics from Bangladesh
Incepta Pharmaceuticals
Incepta Pharmaceuticals Ltd. is a Bangladeshi pharmaceutical company founded in 1999 and headquartered in Dhaka. It is privately held and led by Abdul Muktadir, its chairman and managing director.
Incepta makes a broad range of generic medicines, including cancer drugs, as well as biotech products — epoetin, granulocyte colony-stimulating factor (G-CSF) and adalimumab — and human vaccines. In 2015 it was among the first to launch a generic of sofosbuvir for hepatitis C in Bangladesh.
Production is based at two sites near Dhaka, in Zirabo (Savar) and Dhamrai. The Zirabo site holds a UK MHRA GMP certificate for tablets and capsules, and in 2025 a unit at Dhamrai was inspected by the WHO prequalification programme. According to the company, Incepta exports to more than 100 countries.
Unifarm carries Incepta's oncology medicines: Palbocent 125 (palbociclib), Crizocent 250 (crizotinib) and Osicent (osimertinib).